Electronic Supplementary Material (ESI) for Organic Chemistry Frontiers. This journal is © the Partner Organisations 2020

Supporting Information

General Information	2
General Procedures	3
Analytical Data for Substrates and Products	4
References	27
¹ H and ¹³ C NMR Spectra	28
HPLC Data	66

General Information

Proton (¹H NMR) and carbon (¹³C NMR) nuclear magnetic resonance spectra were recorded at 500 MHz and 126 MHz, respectively. The chemical shifts are given in parts per million (ppm) on the delta (δ) scale. The solvent peak was used as a reference value, for ¹H NMR: CDCl₃ = 7.26 ppm, for ¹³C NMR: CDCl₃ = 77.23. Analytical TLC was performed on precoated silica gel GF254 plates. Column chromatography was carried out on silica gel (200–300 mesh). Optical rotations were measured using a 2.5 mL cell with a 10 cm path length on Hanon P850 Automatic Polarimeter and concentrations (c) were reported in g×(100 mL)⁻¹. Enantiomeric excesses weredetermined by HPLC using a Daicel Chiralpak and Chiralcel column withhexane/*i*-PrOH as the eluent on Dionex instrument. All the substrates adopted in this work were known and prepared following established procedure.¹

General Procedure

To a solution of **2** (1 mmol, 1.0 equiv) in THF/CH₂Cl₂ (1.5 mL/0.5 mL) was added $L/Ni(OTf)_2$ (0.1 mmol, 10 mol%) at -40 °C. Then a solution of 2,4,6-collidine (0.396 mL, 3 mmol, 3.0 equiv) and BF₃·OEt₂ (0.495 mL, 4 mmol, 4.0 equiv) were added to the reaction mixture, and it was allowed to warm to rt in 5 min. After that, **1ab** (0.41 mL, 2.5 mmol, 2.5 equiv) was added and the resulting mixture was stirred for another 2h. The solvent was removed and the residue was purified by silica gel chromatography to give the desired product.

Analytical Data for Substrates and Products

Preparation of L/Ni(OTf)₂

To a suspension of L (0.5 mmol) in acetonitrile (10 mL) was added anhydrous NiBr₂ (109 mg, 0.5 mmol) and one drop of water. The mixture was stirred at reflux overnight before the solvent was removed. The residue was triturated with toluene, followed by filtration to afford a violet solid. To a stirred suspension of the solid (0.4 mmol) in CH₂Cl₂ (4 mL) was added anhydrous AgOTf (204 mg, 0.8 mmol). After filtration through celite, the solvent was removed under reduced pressure to afford the expected L/Ni(OTf)₂.



(*R*)-2-Phenyl-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)ethanone (3a)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3a** in 56% yield (164.6 mg) and **3a'** in 30% yield (86.1 mg), corresponding to a combined yield of 86% (250.7 mg) and a 1.9:1 d.r.. ¹H NMR (500 MHz, CDCl₃) δ 7.47 (dd, J = 5.2, 3.3 Hz, 2H), 7.37–7.30 (m, 2H), 7.28 (dt, J = 4.8, 1.9 Hz, 1H), 6.29 (d, J = 8.3 Hz, 1H), 4.58–4.47 (m, 2H), 4.43–4.34 (m, 1H), 4.25 (ddd, J = 11.3, 9.5, 8.6 Hz, 1H), 4.13 (ddd, J = 11.3, 9.3, 6.4 Hz, 1H), 3.87–3.80 (m, 1H), 3.73 (td, J = 7.9, 6.2 Hz, 1H), 2.12 (m, 1H), 1.98–1.82 (m, 2H), 1.71 (ddt, J = 12.3, 8.6, 6.9 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 173.7, 136.1, 129.8, 128. 7, 127.9, 81.1, 68.5, 66.2, 52.9, 47.7, 30.5, 25.8; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 5/95, 1.0 mL/min, 277 nm), retention time: t_{major} = 27.170 min, t_{minor} = 29.370 min, ee = 98%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-Phenyl-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)ethanone (3a')

¹H NMR (500 MHz, CDCl₃) δ 7.50 (dt, J = 3.3, 2.0 Hz, 2H), 7.35–7.30 (m, 2H), 7.30–7.26 (m, 1H), 6.29 (d, J = 9.8 Hz, 1H), 4.67 (dt, J = 9.8, 6.5 Hz, 1H), 4.48 (ddd, J = 9.4, 8.9, 7.5 Hz, 1H), 4.40 (td, J = 9.1, 7.5 Hz, 1H), 4.33 (ddd, J = 11.2, 9.5, 7.4 Hz, 1H), 4.14 (ddd, J = 11.2, 9.3, 7.5 Hz, 1H), 3.94 (dt, J = 13.9, 7.0 Hz, 1H), 3.83 (td, J = 7.9, 6.0 Hz, 1H), 2.02–1.91 (m, 1H), 1.90–1.80 (m, 1H), 1.74–1.64 (m, 1H), 1.63–1.52 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.6, 174.1, 135.1, 129.6, 128.7, 127.9, 81.9, 68.6, 66.2, 52.9, 47.5, 29.4, 25.5; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 275 nm), retention time: t_{minor} = 8.327 min, t_{major} = 12.540 min, ee = 96%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(4-Methoxyphenyl)-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)ethan-1-one (3b)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc100:0 to 99:1) affording **3b** in 47% yield (149.7 mg) and **3b'** in 23% yield (74.3 mg), corresponding to a combined yield of 70% (224.0 mg) and a 2:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.44–7.36 (m, 2H), 6.90–6.82 (m, 2H), 6.21 (d, *J* = 8.2 Hz, 1H), 4.51 (m,2H), 4.40 (q, *J* = 9.0 Hz, 1H), 4.29–4.22 (m, 1H), 4.12 (ddd, *J* = 11.3, 9.3, 6.4 Hz, 1H), 3.85–3.78 (m, 1H), 3.79 (d, *J* = 7.1 Hz, 3H), 3.72 (dd, *J* = 14.2, 7.8 Hz, 1H), 2.15–2.07 (m, 1H), 1.93–1.84 (m, 2H), 1.72–1.66 (m,

1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 174.0, 159.3, 130.9, 128.1, 114.2, 81.1, 68.5, 66.2, 55.4, 52.2, 47.7, 30.5, 29.9, 25.8; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 276 nm), retention time: t_{minor} = 15.447 min, t_{major} = 16.733 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(4-Methoxyphenyl)-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl))ethan-1-one (3b')

¹H NMR (500 MHz, CDCl₃) δ 7.51–7.35 (m, 2H), 6.92–6.80 (m, 2H), 6.20 (d, J = 9.9 Hz, 1H), 4.63 (dt, J = 9.9, 6.5 Hz, 1H), 4.49 (td, J = 9.2, 7.6 Hz, 1H), 4.42 (m, 1H), 4.34 (ddd, J = 11.2, 9.6, 7.4 Hz, 1H), 4.14 (ddd, J = 11.2, 9.3, 7.5 Hz, 1H), 3.92 (dt, J = 13.9, 7.0 Hz, 1H), 3.84–3.80 (m, 1H), 3.78 (s, 3H), 1.98–1.90 (m, 1H), 1.87–1.79 (m, 1H), 1.72–1.66 (m, 1H), 1.59–1.51 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.6, 174.5, 159.4, 130.7, 127.3, 114.2, 81.9, 68.8, 66.2, 55.4, 52.2, 47.6, 29.5, 25.6; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 276 nm), retention time: t_{major} = 11.373 min, t_{minor} = 15.463 min, ee = 96%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-((*S*)-Tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)-2-(p-tolyl)ethanone (3c)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3c** in 51% yield (154.8 mg) and **3c'** in 24% yield (73.4 mg), corresponding to a combined yield of 75% (228.2 mg) and a 2.1:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.36 (d, *J* = 8.1 Hz, 2H),

7.14 (d, J = 7.9 Hz, 2H), 6.23 (d, J = 8.4 Hz, 1H), 4.56–4.46 (m, 2H), 4.38 (q, J = 8.9 Hz, 1H), 4.29–4.20 (m, 1H), 4.11 (ddd, J = 11.3, 9.3, 6.3 Hz, 1H), 3.87–3.80 (m, 1H), 3.72 (td, J = 7.8, 6.3 Hz, 1H), 2.31 (s, 3H), 2.16–2.08 (m, 1H), 1.95–1.82 (m, 2H), 1.74–1.66 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 173.9, 137.6, 133.1, 129.6, 129.4, 81.2, 68.5, 66.2, 52.7, 47.7, 30.6, 25.8, 21.4; HPLC: the ee value was determined by HPLC analysis (Chiralcel OD-H, *i*-PrOH/Hexane = 30/70, 1.0 mL/min, 274 nm), retention time: t_{minor} = 10.793 min, t_{major} = 23.550 min, ee = 91%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-((*R*)-Tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)-2-(p-tolyl)ethanone (3c')

¹H NMR (500 MHz, CDCl₃) δ 7.31 (d, *J* = 8.1 Hz, 2H), 7.06 (d, *J* = 7.9 Hz, 2H), 6.16 (d, *J* = 9.9 Hz, 1H), 4.58 (dt, *J* = 9.8, 6.5 Hz, 1H), 4.46–4.39 (m, 1H), 4.37–4.31 (m, 1H), 4.27 (ddd, *J* = 11.2, 9.5, 7.5 Hz, 1H), 4.07 (ddd, *J* = 11.2, 9.2, 7.4 Hz, 1H), 3.89–3.83 (m, 1H), 3.75 (td, *J* = 7.9, 6.0 Hz, 1H), 2.25 (s, 3H), 1.91–1.83 (m, 1H), 1.81–1.72 (m, 1H), 1.65–1.59 (m, 1H), 1.53–1.48 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.6, 174.4, 137.8, 132.2, 129.6, 129.6, 81.9, 68.8, 66.2, 52.7, 47.7, 29.5, 25.7, 21.3; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 274 nm), retention time: t_{minor} = 9.020 min, t_{major} = 11.583 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(R)-2-([1,1'-Biphenyl]-4-yl)-2-((S)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-

yl)ethan-1-one (3d)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3d** in 56% yield (207.2 mg) and **3d'** in 28% yield (101.3 mg), corresponding to a combined yield of 86% (308.5 mg) and a 2:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.61–7.53 (m, 6H), 7.42 (t, *J* = 7.7 Hz, 2H), 7.33 (t, *J* = 7.4 Hz, 1H), 6.35 (d, *J* = 8.4 Hz, 1H), 4.64–4.56 (m, 1H), 4.51 (td, *J* = 9.3, 6.5 Hz, 1H), 4.40 (q, *J* = 9.0 Hz, 1H), 4.30–4.23 (m, 1H), 4.15 (ddd, *J* = 11.3, 9.3, 6.5 Hz, 1H), 3.87 (dd, *J* = 15.0, 6.9 Hz, 1H), 3.76 (dd, *J* = 14.1, 7.8 Hz, 1H), 2.20–2.12 (m, 1H), 1.98–1.87 (m, 2H), 1.78–1.71 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 173.7, 141.0, 140.8, 135.2, 130.2, 128.9, 127.4, 127.3, 81.2, 68.6, 66.2, 52.7, 47.7, 30.6, 25.8; HPLC: the ee value was determined by HPLC analysis (Chiralcel OD-H, *i*-PrOH/Hexane = 35/65, 1.0 mL/min, 278 nm), retention time: t_{minor} = 21.160 min, t_{major} = 29.237 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-([1,1'-Biphenyl]-4-yl)-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)ethan-1-one (3d')

¹H NMR (500 MHz, CDCl₃) δ 7.57–7.43 (m, 6H), 7.37 (dd, J = 10.4, 4.8 Hz, 2H), 7.30–7.25 (m, 1H), 6.26 (d, J = 9.8 Hz, 1H), 4.64 (dt, J = 9.8, 6.5 Hz, 1H), 4.48–4.41 (m, 1H), 4.38 (m, 1H), 4.30 (ddd, J = 11.2, 9.6, 7.3 Hz, 1H), 4.11 (ddd, J = 11.2, 9.3, 7.6 Hz, 1H), 3.91–3.86 (m, 1H), 3.78 (td, J = 7.8, 6.0 Hz, 1H), 1.96–1.87 (m, 1H), 1.84–1.75 (m, 1H), 1.71–1.64 (m, 1H), 1.59–1.54 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.7, 174.3, 140.9, 140.8, 134.2, 130.1, 129.0, 127.6, 127.6, 127.2, 82.1, 68.8, 66.3, 52.8, 47.7, 29.7, 25.7; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 5/95, 1.0 mL/min, 268 nm), retention time: t_{minor} = 49.057 min, t_{major} = 51.497 min, ee = 96%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(4-Chlorophenyl)-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)e than-1-one (3e)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3e** in 55% yield (179.1 mg) and **3d'** in 25% yield (80.9 mg), corresponding to a combined yield of 80% (260 mg) and a 2.2:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.44–7.38 (m, 2H), 7.32–7.27 (m, 2H), 6.25 (d, *J* = 8.1 Hz, 1H), 4.54–4.46 (m, 2H), 4.46–4.38 (m, 1H), 4.25 (ddd, *J* = 11.3, 9.5, 8.3 Hz, 1H), 4.14 (ddd, *J* = 11.4, 9.4, 6.8 Hz, 1H), 3.84–3.79 (m, 1H), 3.75–3.69 (m, 1H), 2.16–2.07 (m, 1H), 1.92–1.84 (m, 2H), 1.70–1.62 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.3, 173.3, 134.5, 133.9, 131.2, 128.8, 80.9, 68.5, 66.3, 52.4, 47.6, 30.5, 25.8; HPLC: the evalue was determined by HPLC analysis (Chiralpak AS-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 274 nm), retention time: t_{minor} = 20.097 min, t_{major} = 22.007 min, ee = 95%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(4-Chlorophenyl)-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)e than-1-one (3e')

¹H NMR (500 MHz, CDCl₃) δ 7.43–7.33 (m, 2H), 7.23 (d, J = 8.5 Hz, 2H), 6.18 (d, J = 9.8 Hz, 1H), 4.54 (dt, J = 9.8, 6.5 Hz, 1H), 4.47–4.36 (m, 2H), 4.28 (ddd, J = 11.3, 9.6, 7.1 Hz, 1H), 4.12–4.06 (m, 1H), 3.88–3.82 (m, 1H), 3.76 (td, J = 7.9, 5.9 Hz, 1H), 1.92–1.83 (m, 1H), 1.81–1.74 (m, 1H), 1.66–1.59 (m, 1H), 1.48–1.42 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 173.8, 133.9, 133.5, 130.8, 128.8, 81.8, 68.6, 66.2, 52.3, 47.5, 29.4, 25.5; HPLC: the ee value was determined by HPLC analysis

(Chiralpak AD-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 273 nm), retention time: $t_{minor} = 9.977 \text{ min}, t_{major} = 11.700 \text{ min}, ee = 97\%$. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(4-Fluorophenyl)-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)et han-1-one (3f)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3f** in 56% yield (172.6 mg) and **3f**' in 25% yield (75.3 mg), corresponding to a combined yield of 81% (248 mg) and a 2.3:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.51–7.39 (m, 2H), 7.08–6.96 (m, 2H), 6.27 (d, *J* = 8.1 Hz, 1H), 4.56–4.46 (m, 2H), 4.46–4.38 (m, 1H), 4.26 (ddd, *J* = 11.3, 9.5, 8.3 Hz, 1H), 4.14 (ddd, *J* = 11.4, 9.4, 6.8 Hz, 1H), 3.86–3.79 (m, 1H), 3.76–3.69 (m, 1H), 2.16–2.07 (m, 1H), 1.93–1.84 (m, 2H), 1.71–1.63 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 173.6, 162.6 (d, *J* = 246.3 Hz), 131.8 (d, *J* = 3.2 Hz), 131.5 (d, *J* = 8.0 Hz), 115.6 (d, *J* = 21.3 Hz), 81.1, 68.5, 66.2, 52.2, 47.6, 30.5, 25.8; HPLC: the evalue was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 290 nm), retention time: t_{minor} = 11.230 min, t_{major} = 12.700 min, ee = 95%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(4-Fluorophenyl)-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)e than-1-one (3f')

¹H NMR (500 MHz, CDCl₃) δ 7.49–7.35 (m, 2H), 7.03–6.87 (m, 2H), 6.19 (d, J = 9.8 Hz, 1H), 4.55 (dt, J = 9.8, 6.5 Hz, 1H), 4.48–4.34 (m, 2H), 4.28 (ddd, J = 11.3, 9.6,

7.1 Hz, 1H), 4.09 (ddd, J = 11.3, 9.4, 7.9 Hz, 1H), 3.85 (dt, J = 14.0, 7.0 Hz, 1H), 3.75 (td, J = 7.8, 6.0 Hz, 1H), 1.92–1.83 (m, 1H), 1.82–1.73 (m, 1H), 1.66–1.58 (m, 1H), 1.50–1.42 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 173.6, 162.4 (d, J =246.9 Hz), 131.8 (d, J = 8.0 Hz), 131.5 (d, J = 3.1 Hz), 115.5 (d, J = 21.3 Hz), 81.1, 68.5, 66.2, 52.1, 47.6, 30.5, 25.8; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 277 nm), retention time: t_{minor} = 8.967 min, t_{major} = 11.777 min, ee = 98%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(3-Methoxyphenyl)-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl))ethan-1-one (3g)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3g** in 47% yield (150.2 mg) and **3g'** in 23% yield (74.1 mg), corresponding to a combined yield of 70% (224.3 mg) and a 2:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.23 (t, *J* = 8.0 Hz, 1H), 7.05 (t, *J* = 4.3 Hz, 2H), 6.83–6.79 (m, 1H), 6.27 (d, *J* = 8.4 Hz, 1H), 4.56–4.46 (m, 2H), 4.38 (q, *J* = 9.0 Hz, 1H), 4.26–4.20 (m, 1H), 4.11 (ddd, *J* = 11.3, 9.3, 6.4 Hz, 1H), 3.87–3.82 (m, 1H), 3.79 (s, 3H), 3.73 (td, *J* = 7.9, 6.2 Hz, 1H), 2.16–2.07 (m, 1H), 1.96–1.84 (m, 2H), 1.75–1.68 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 173.6, 159.7, 137.6, 129.5, 122.2, 115.5, 113.4, 81.1, 68.5, 66.2, 55.4, 52.8, 47.6, 30.5, 25.7; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 277 nm), retention time: t_{major} = 11.743 min, t_{minor} = 17.243 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(3-Methoxyphenyl)-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl))ethan-1-one (3g')

¹H NMR (500 MHz, CDCl₃) δ 7.25–7.19 (m, 1H), 7.07 (dd, J = 4.9, 3.2 Hz, 2H), 6.86–6.77 (m, 1H), 6.25 (d, J = 9.8 Hz, 1H), 4.66 (dt, J = 9.8, 6.4 Hz, 1H), 4.49 (td, J = 9.2, 7.5 Hz, 1H), 4.45–4.39 (m, 1H), 4.34 (ddd, J = 11.2, 9.6, 7.5 Hz, 1H), 4.15 (ddd, J = 11.3, 9.3, 7.5 Hz, 1H), 3.96–3.90 (m, 1H), 3.85–3.81 (m, 1H), 3.80 (s, 3H), 2.00–1.90 (m, 1H), 1.88–1.80 (m, 1H), 1.74–1.66 (m, 1H), 1.62–1.53 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.68, 174.1, 159.9, 136.7, 129.7, 122.1, 115.3, 113.5, 81.9, 68.7, 66.2, 55.5, 52.9, 47.7, 29.5, 25.6; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 277 nm), retention time: t_{minor} = 9.200 min, t_{major} = 16.480 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(3-Chlorophenyl)-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)e than-1-one (3h)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3h** in 58% yield (187.5 mg) and **3h'** in 23% yield (75.8 mg), corresponding to a combined yield of 81% (263.3 mg) and a 2.5:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.47 (d, *J* = 0.8 Hz, 1H), 7.40–7.35 (m, 1H), 7.26 (dd, *J* = 4.1, 2.0 Hz, 2H), 6.29 (d, *J* = 8.2 Hz, 1H), 4.56–4.49 (m, 2H), 4.48–4.40 (m, 1H), 4.30–4.23 (m, 1H), 4.20–4.13 (m, 1H), 3.86–3.80 (m, 1H), 3.77–3.70 (m, 1H), 2.17–2.08 (m, 1H), 1.95–1.85 (m, 2H), 1.72–1.65 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 173.1, 138.0, 134.4, 129.8, 129.7, 128.4, 128.1, 81.0, 68.5, 66.3, 52.5, 47.6, 30.5, 25.7; HPLC: the ee value was determined by HPLC

analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 273 nm), retention time: $t_{major} = 9.283$ min, $t_{minor} = 9.893$ min, ee = 98%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(3-Chlorophenyl)-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)e than-1-one (3h')

¹H NMR (500 MHz, CDCl₃) δ 7.50 (s, 1H), 7.42–7.37 (m, 1H), 7.29–7.24 (m, 2H), 6.27 (d, J = 9.8 Hz, 1H), 4.62 (dt, J = 9.8, 6.5 Hz, 1H), 4.55–4.43 (m, 2H), 4.39–4.32 (m, 1H), 4.21–4.14 (m, 1H), 3.92 (dd, J = 14.6, 7.5 Hz, 1H), 3.82 (td, J = 7.8, 6.2 Hz, 1H), 1.99–1.90 (m, 1H), 1.90–1.82 (m, 1H), 1.75–1.68 (m, 1H), 1.59–1.51 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.7, 173.8, 137.2, 134.7, 130.0, 129.6, 128.3, 128.1, 82.0, 68.8, 66.4, 52.6, 47.6, 29.6, 25.6; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 275 nm), retention time: t_{minor} = 7.303 min, t_{major} = 11.403 min, ee = 99%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(2-Chlorophenyl)-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)e than-1-one (3i)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3i** in 61% yield (197.5 mg) and **3i'** in 22% yield (72.0 mg), corresponding to a combined yield of 83% (269.5 mg) and a 2.7:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.69 (dd, J = 7.6, 1.9 Hz, 1H), 7.38 (dd, J = 7.7, 1.6 Hz, 1H), 7.26–7.18 (m, 2H), 6.58 (d, J = 6.3 Hz, 1H), 4.70–4.59 (m, 1H), 4.57–4.43 (m, 2H), 4.28–4.17 (m, 2H), 3.85 (dt, J = 13.4, 6.7 Hz, 1H), 3.74

(dt, J = 8.3, 6.6 Hz, 1H), 2.08–2.00 (m, 1H), 1.88–1.75 (m, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 185.1, 172.9, 135.7, 133.5, 131.3, 129.8, 128.9, 126.9, 80.5, 69.0, 66.4, 49.4, 47.9, 29.7, 25.9; HPLC: the ee value was determined by HPLC analysis (Chiralpak AS-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 272 nm), retention time: t_{minor} = 17.197 min, t_{major} = 21.880 min, ee = 98%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(2-Chlorophenyl)-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)e than-1-one (3i')

¹H NMR (500 MHz, CDCl₃) δ 7.69 (dd, J = 7.7, 1.9 Hz, 1H), 7.39 (dd, J = 7.7, 1.6 Hz, 1H), 7.26–7.19 (m, 2H), 6.60 (d, J = 9.6 Hz, 1H), 4.64 (dt, J = 9.6, 6.0 Hz, 1H), 4.52 (td, J = 9.2, 6.8 Hz, 1H), 4.47–4.39 (m, 1H), 4.36–4.26 (m, 1H), 4.21–4.14 (m, 1H), 4.03 (td, J = 7.7, 5.7 Hz, 1H), 3.84–3.77 (m, 1H), 2.12–2.05 (m, 1H), 1.90–1.84 (m, 1H), 1.82–1.74 (m, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 185.2, 174.0, 135.2, 133.6, 130.4, 130.3, 129.0, 127.2, 83.1, 69.3, 66.2, 49.7, 47.9, 29.3, 25.8; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 281 nm), retention time: t_{minor} = 11.260 min, t_{major} = 17.353 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(Naphthalen-1-yl)-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl)e than-1-one (3j)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3j** in 59% yield (200.3 mg) and **3j'** in 22% yield (76.2 mg), corresponding to a combined yield of 81% (276.5 mg) and a 2.6:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 8.34 (d, *J* = 8.6 Hz, 1H), 7.84 (d, *J* = 8.0 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 1H), 7.71 (d, *J* = 7.3 Hz, 1H), 7.56 (ddd,

J = 8.4, 6.8, 1.2 Hz, 1H), 7.50–7.42 (m, 2H), 7.08 (d, J = 7.4 Hz, 1H), 4.68 (q, J = 6.8 Hz, 1H), 4.47 (td, J = 8.9, 6.3 Hz, 1H), 4.32 (dd, J = 17.5, 8.7 Hz, 1H), 4.29–4.22 (m, 1H), 4.12 (ddd, J = 11.1, 9.0, 6.3 Hz, 1H), 3.91–3.85 (m, 1H), 3.72 (td, J = 8.0, 5.6 Hz, 1H), 2.07–1.95 (m, 3H), 1.92–1.84 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.5, 173.9, 134.2, 132.9, 132.5, 128.9, 128.6, 126.4, 126.3, 125.8, 125.5, 124.8, 81.8, 68.9, 66.3, 48.3, 47.9, 30.2, 26.0; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 279 nm), retention time: t_{major} = 11.733 min, t_{minor} = 14.167 min, ee = 95%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-(Naphthalen-1-yl)-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxooxazolidin-3-yl) ethan-1-one (3j')

¹H NMR (500 MHz, CDCl₃) δ 8.54 (d, *J* = 8.6 Hz, 1H), 7.85 (d, *J* = 8.1 Hz, 1H), 7.82–7.76 (m, 2H), 7.58 (dd, *J* = 11.2, 4.1 Hz, 1H), 7.53–7.43 (m, 2H), 7.08 (d, *J* = 9.5 Hz, 1H), 4.85–4.76 (m, 1H), 4.55–4.46 (m, 1H), 4.40–4.31 (m, 2H), 4.17–4.10 (m, 1H), 4.09–4.03 (m, 1H), 3.88–3.82 (m, 1H), 2.03–1.97 (m, 1H), 1.89–1.79 (m, 1H), 1.71–1.64 (m, 1H), 1.60–1.53 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 185.8, 174.9, 134.9, 132.6, 132.1, 129.0, 128.6, 126.6, 125.9, 125.6, 125.0, 83.5, 69.2, 66.3, 48.1, 29.6, 25.9; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 279 nm), retention time: t_{minor} = 10.623 min, t_{major} = 18.690 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-Phenyl-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-yl)ethan-1-on e (3l)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **31** in 51% yield (156.4 mg) and **31'** in 28% yield (86.1 mg), corresponding to a combined yield of 79% (242.5 mg) and a 1.8:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.44–7.38 (m, 2H), 7.36–7.30 (m, J = 10.0, 4.7 Hz, 2H), 7.30–7.27 (m, 1H), 6.08 (d, J = 8.1 Hz, 1H), 4.59–4.43 (m, J = 11.6, 10.9, 5.7 Hz, 3H), 3.80 (dd, J = 11.0, 4.1 Hz, 1H), 3.72 (dd, J = 14.2, 7.6 Hz, 1H), 3.16 (dd, J = 8.2, 6.8 Hz, 2H), 2.16–2.09 (m, J = 12.3, 6.6 Hz, 1H), 1.91–1.85 (m, J = 10.3, 3.0 Hz, 2H), 1.80–1.74 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 201.8, 174.5, 136.4, 129.6, 128.7, 127.8, 81.0, 68.5, 56.9, 54.9, 30.5, 28.3, 25.8; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 5/95, 1.0 mL/min, 311 nm), retention time: t_{major} = 20.240 min, t_{minor} = 22.417 min, ee = 95%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-Phenyl-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-yl)ethan-1-on e (3l')

¹H NMR (500 MHz, CDCl₃) δ 7.45 (dd, J = 5.2, 3.3 Hz, 2H), 7.34–7.30 (m, 2H), 7.29–7.26 (m, 1H), 5.97 (d, J = 9.7 Hz, 1H), 4.72–4.66 (m, 1H), 4.62 (dt, J = 9.7, 6.5 Hz, 1H), 4.50 (dt, J = 12.1, 7.7 Hz, 1H), 3.91 (dt, J = 14.0, 7.0 Hz, 1H), 3.82 (td, J =7.9, 6.0 Hz, 1H), 3.31–3.23 (m, 1H), 3.20–3.12 (m, 1H), 1.94–1.87 (m, 1H), 1.85–1.79 (m, 1H), 1.69–1.62 (m, 1H), 1.56–1.49 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 202.0, 174.9, 135.4, 129.6, 128.7, 127.9, 82.5, 68.7, 56.9, 54.9, 29.6, 28.4, 25.6; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 310 nm), retention time: t_{minor} = 8.010 min, t_{major} = 11.423 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*,*E*)-4-Phenyl-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-yl)but-3-en-1-one (3m)

The compounds were prepared according to general procedure using CH₃CO₂CH₃/CH₂Cl₂ (3:1, v/v) as solvent and L4/Ni(OTf)₂ as catalyst and purified by silica gel chromatography (CH₂Cl₂/EtOAc 99:1) affording **3m** in 36% yield (120.3 mg) and 3m' in 30% yield (99.7 mg), corresponding to a combined yield of 66% (220.0 mg) and a 1.2:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.43–7.38 (m, 2H), 7.31 (dd, J = 10.3, 4.8 Hz, 2H), 7.25-7.20 (m, 1H), 6.61-6.50 (m, 1H), 6.45-6.34 (m, 1H),5.62 (dd, J = 9.0, 5.3 Hz, 1H), 4.64–4.54 (m, 2H), 4.45–4.40 (m, 1H), 3.88–3.83 (m, 1H), 3.80–3.75 (m, 1H), 3.33–3.22 (m, 2H), 2.08–2.02 (m, 1H), 1.90–1.83 (m, 2H), 1.80–1.73 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 202.1, 174.5, 136.9, 134.8, 128.7, 127.9, 126.7, 124.4, 80.1, 69.0, 56. 9, 52.8, 29.7, 28.4, 25.9; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, i-PrOH/Hexane = 25/75, 1.0 mL/min, 311 nm), retention time: $t_{minor} = 12.590 \text{ min}$, $t_{major} = 18.423 \text{ min}$, ee = 95%. The NMR spectral data is consistent with reported literature values.²



(*R*,*E*)-4-Phenyl-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-yl)but-3-en-1-one (3m')

¹H NMR (500 MHz, CDCl₃) δ 7.40–7.36 (m, 2H), 7.34–7.29 (m, J = 7.5 Hz, 2H), 7.27 – 7.21 (m, 1H), 6.64 (d, J = 16.1 Hz, 1H), 6.21 (dd, J = 16.0, 9.0 Hz, 1H), 5.58–5.45 (m, J = 9.1 Hz, 1H), 4.71 (ddd, J = 12.2, 7.8, 5.5 Hz, 1H), 4.51 (ddd, J =12.1, 8.9, 7.8 Hz, 1H), 4.44 (dt, J = 9.3, 6.3 Hz, 1H), 3.89 (dt, J = 13.3, 6.8 Hz, 1H), 3.80 (dt, J = 14.2, 7.0 Hz, 1H), 3.34 (ddd, J = 11.0, 8.9, 7.9 Hz, 1H), 3.21 (ddd, J =11.0, 7.7, 5.5 Hz, 1H), 2.02–1.85 (m, 3H), 1.76 (ddd, J = 10.9, 7.3, 5.8 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 202.2, 175.1, 136.8, 134.8, 128.8, 128.1, 126.6, 124.2, 81.4, 68.7, 56.7, 53.2, 29.6, 28.6, 25.7; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 310 nm), retention time: $t_{minor} = 12.850$ min, $t_{major} = 14.733$ min, ee = 90%. The NMR spectral data is consistent with reported literature values.²



(*R*,*E*)-4-(4-Bromophenyl)-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-yl)but-3-en-1-one (3n)

The compounds were prepared according to general procedure using CH₃CO₂CH₃/CH₂Cl₂ (3:1, v/v) as solvent and L4/Ni(OTf)₂ as catalyst and purified by silica gel chromatography (CH₂Cl₂/EtOAc 99:1) affording **3n** in 52% yield (246.9 mg) and 3n' in 25% yield (122.1 mg), corresponding to a combined yield of 77% (369.0 mg) and a 2:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.45–7.39 (m, 2H), 7.28–7.25 (m, 2H), 6.54–6.46 (m, 1H), 6.43–6.34 (m, 1H), 5.62 (dd, *J* = 8.8, 5.4 Hz, 1H), 4.65–4.51 (m, 2H), 4.40 (td, J = 7.0, 5.6 Hz, 1H), 3.88–3.81 (m, 1H), 3.80–3.74 (m, 1H), 3.34–3.22 (m, 2H), 2.08–2.01 (m, 1H), 1.90–1.83 (m, 2H), 1.77–1.70 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 202.2, 174.2, 135.8, 133.5, 131.8, 128.3, 125.4, 121.7, 80.1, 69.0, 56.8, 52.7, 29.7, 28.4, 25.8; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, i-PrOH/Hexane = 25/75, 1.0 mL/min, 271 nm), retention time: $t_{minor} = 17.247 \text{ min}$, $t_{major} = 29.000 \text{ min}$, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*,*E*)-4-(4-Bromophenyl)-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-y l)but-3-en-1-one (3n')

¹H NMR (500 MHz, CDCl₃) δ 7.43 (d, *J* = 8.4 Hz, 2H), 7.23 (d, *J* = 8.4 Hz, 2H), 6.57 (d, *J* = 16.0 Hz, 1H), 6.20 (dd, *J* = 16.0, 9.0 Hz, 1H), 5.50 (t, *J* = 9.1 Hz, 1H), 4.72 (ddd, *J* = 12.6, 7.8, 5.1 Hz, 1H), 4.51 (ddd, *J* = 12.0, 9.3, 7.8 Hz, 1H), 4.42 (dt, *J* = 9.2, 6.3 Hz, 1H), 3.88 (dt, *J* = 13.5, 6.9 Hz, 1H), 3.80 (dd, *J* = 14.0, 7.5 Hz, 1H), 3.37 (ddd, *J* = 10.7, 9.4, 8.0 Hz, 1H), 3.22 (ddd, *J* = 11.1, 7.7, 5.1 Hz, 1H), 2.03–1.87 (m, *J* = 27.3, 19.5, 9.8, 5.3 Hz, 3H), 1.76–1.69 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 202.3, 174.9, 135.7, 133.5, 131.6, 128.2, 125.1, 121.8, 81.5, 68.7, 56.7, 53.2, 29.6, 28.7, 25.7; HPLC: the ee value was determined by HPLC analysis (Chiralpak AS-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 268 nm), retention time: t_{minor} = 18.823 min, t_{major} = 28.987 min, ee = 92%. The NMR spectral data is consistent with reported literature values.²



(*R*,*E*)-2-((*S*)-Tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-yl)hept-3-en-1-one (30)

The compounds were prepared according to general procedure using CH₃CO₂CH₃/CH₂Cl₂ (3:1, v/v) as solvent and L4/Ni(OTf)₂ as catalyst and purified by silica gel chromatography (CH₂Cl₂/petroleum ether 75:25 to 100:0) affording **30** in 42% yield (125.9 mg) and **30'** in 28% yield (83.1 mg), corresponding to a combined yield of 70% (209.0 mg) and a 1.5:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 5.68–5.55 (m, 2H), 5.36 (dd, J = 7.9, 5.5 Hz, 1H), 4.59–4.49 (m, 2H), 4.29 (td, J = 7.0, 5.6 Hz, 1H), 3.84–3.79 (m, 1H), 3.76–3.71 (m, 1H), 3.31–3.20 (m, 2H), 2.06–2.01 (m, 2H), 2.01-1.95 (m, 1H), 1.88-1.81 (m, 2H), 1.75-1.67 (m, 1H), 1.43-1.35 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 201.8, 175.0, 136.4, 124.4, 79.9, 68.9, 56.9, 52.5, 34.9, 29.5, 28.46, 25.8, 22.4, 13.8; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 10/90, 1.0 mL/min, 279 nm),

retention time: $t_{minor} = 17.057 \text{ min}$, $t_{major} = 21.230 \text{ min}$, ee = 90%. The NMR spectral data is consistent with reported literature values.²



(*R*,*E*)-2-((*R*)-Tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-yl)hept-3-en-1-one (30')

¹H NMR (500 MHz, CDCl₃) δ 5.72–5.61 (m, 1H), 5.42–5.33 (m, 1H), 5.24 (t, *J* = 9.1 Hz, 1H), 4.69–4.61 (m, 1H), 4.51–4.44 (m, 1H), 4.27 (dt, *J* = 9.3, 6.3 Hz, 1H), 3.81 (dt, *J* = 13.4, 6.9 Hz, 1H), 3.73 (td, *J* = 7.6, 6.1 Hz, 1H), 3.33–3.28 (m, 1H), 3.22–3.16 (m, 1H), 1.99–1.81 (m, 5H), 1.68–1.62 (m, 1H), 1.39–1.32 (m, 2H), 0.84 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 201.9, 175.6, 136.4, 124.5, 81.3, 68.5, 56.7, 53.1, 34.8, 29.4, 28.6, 25.5, 22.3, 13.7; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 5/95, 1.0 mL/min, 309 nm), retention time: t_{minor} = 10.003 min, t_{major} = 13.390 min, ee = 86%. The NMR spectral data is consistent with reported literature values.²



(*R*,*E*)-4-Phenyl-2-((*S*)-tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-yl)pent-3-en -1-one (3p)

The compounds were prepared according to general procedure using $CH_3CO_2CH_3/CH_2Cl_2$ (3:1, v/v) as solvent and L4/Ni(OTf)₂ as catalyst and purified by silica gel chromatography (CH₂Cl₂/EtOAc 99:1) affording **3p** in 45% yield (157.9 mg) and **3p'** in 21% yield (71.0 mg), corresponding to a combined yield of 66% (228.9 mg) and a 2.2:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.46–7.39 (m, 2H), 7.34–7.29 (m, 2H), 7.26–7.23 (m, 1H), 6.01 (d, *J* = 2.3 Hz, 2H), 4.64–4.51 (m, 2H), 4.44–4.39 (m, 1H), 3.85 (dt, *J* = 13.8, 6.9 Hz, 1H), 3.81–3.75 (m, 1H), 3.32 (dt, *J* = 11.0, 8.0 Hz, 1H), 3.28–3.21 (m, 1H), 2.10 (s, 3H), 2.05–1.98 (m, 1H), 1.90–1.82 (m, 2H), 1.82–1.75 (m,

1H); ¹³C NMR (126 MHz, CDCl₃) δ 202.3, 174.9, 143.1, 139.9, 128.3, 127.4, 126.2, 122.2, 80.3, 69.2, 57.0, 48.9, 29.3, 28.5, 26.1, 17.5; HPLC: the ee value was determined by HPLC analysis (Chiralpak OD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 310 nm), retention time: t_{minor} = 10.013 min, t_{major} =13.200 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*,*E*)-4-Phenyl-2-((*R*)-tetrahydrofuran-2-yl)-1-(2-thioxothiazolidin-3-yl)pent-3-e n-1-one (3p')

¹H NMR (500 MHz, CDCl₃) δ 7.43–7.38 (m, 2H), 7.33 (dd, J = 10.2, 4.8 Hz, 2H), 7.27–7.24 (m, J = 6.4, 4.1 Hz, 1H), 5.93 (t, J = 9.5 Hz, 1H), 5.84–5.76 (m, J = 10.0, 1.2 Hz, 1H), 4.66 (ddd, J = 12.1, 7.6, 6.6 Hz, 1H), 4.55 (dt, J = 12.1, 7.8 Hz, 1H), 4.41–4.35 (m, 1H), 3.97–3.91 (m, 1H), 3.80 (dd, J = 14.3, 7.3 Hz, 1H), 3.33 (dt, J =10.9, 7.9 Hz, 1H), 3.25 (ddd, J = 11.0, 7.6, 6.6 Hz, 1H), 2.17 (d, J = 1.2 Hz, 3H), 2.01–1.88 (m, 3H), 1.78–1.72 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 202.4, 175.9, 143.0, 140.0, 128.4, 127.6, 126.1, 122.9, 82.5, 68.9, 56.9, 50.4, 29.6, 28.7, 25.6, 18.1; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 25/75, 1.0 mL/min, 309 nm), retention time: t_{minor} = 7.030 min, t_{major} = 14.483 min, ee = 93%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-Phenyl-2-((*S*)-1-oxaspiro[4.5]decan-2-yl)-1-(2-thioxooxazolidin-3-yl)ethan-1 -one (3q)

The compounds were prepared according to general procedure and purified by silica gel chromatography (CH₂Cl₂/petroleum ether 75:25 to 100:0) affording **3q** in 57% yield (205.8 mg) and **3q'** in 18% yield (63.7 mg), corresponding to a combined yield of 75% (269.5 mg) and a 3.2:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.48 (dd, *J* = 5.2,

3.3 Hz, 2H), 7.34–7.29 (m, 2H), 7.28–7.24 (m, 1H), 6.31 (d, J = 8.2 Hz, 1H), 4.59 (dt, J = 8.1, 6.4 Hz, 1H), 4.49 (td, J = 9.3, 6.8 Hz, 1H), 4.43–4.35 (m, 1H), 4.26–4.20 (m, 1H), 4.17–4.10 (m, 1H), 2.16–2.08 (m, 1H), 1.89–1.81 (m, 1H), 1.80–1.69 (m, 2H), 1.58–1.26 (m, 10H); ¹³C NMR (126 MHz, CDCl₃) δ 185.5, 173.9, 136.2, 130.0, 128.4, 127.6, 83.8, 80.4, 66.1, 53.5, 47.6, 38.6, 37.7, 35.6, 30.3, 25.8, 24.1, 24.1; HPLC: the evalue was determined by HPLC analysis (Chiralpak IB-H, *i*-PrOH/Hexane = 10/90, 1.0 mL/min, 275 nm), retention time: t_{minor} = 13.317 min, t_{major} = 14.720 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-Phenyl-2-((*R*)-1-oxaspiro[4.5]decan-2-yl)-1-(2-thioxooxazolidin-3-yl)ethan-1-one (3q')

¹H NMR (500 MHz, CDCl₃) δ 7.51 (dd, J = 5.2, 3.3 Hz, 2H), 7.34–7.29 (m, 2H), 7.26 (ddd, J = 5.7, 3.7, 1.2 Hz, 1H), 6.23 (d, J = 9.7 Hz, 1H), 4.74–4.64 (m, 1H), 4.50–4.41 (m, 2H), 4.38–4.31 (m, 1H), 4.20–4.13 (m, 1H), 1.78–1.65 (m, 4H), 1.65–1.32 (m, 10H); ¹³C NMR (126 MHz, CDCl₃) δ 185.7, 174.6, 135.5, 129.7, 128.7, 127.8, 84.2, 81.5, 66.3, 54.1, 47.7, 38.8, 37.6, 35.2, 29.2, 25.8, 24.3, 24.1; HPLC: the ee value was determined by HPLC analysis (Chiralpak IB-H, *i*-PrOH/Hexane = 10/90, 1.0 mL/min, 278 nm), retention time: t_{major} = 9.807 min, t_{minor} = 18.560 min, ee = 97%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-Phenyl-2-((*S*)-tetrahydro-2H-pyran-2-yl)-1-(2-thioxooxazolidin-3-yl)ethan-1-one (3r)

The compounds were prepared according to general procedure using CH₂Cl₂ as solvent and purified by silica gel chromatography (CH₂Cl₂/EtOAc 99:1) affording **3r** in 38% yield (116.0 mg) and **3r'** in 25% yield (76.0 mg), corresponding to a combined yield of 63% (192.0 mg) and a 1.5:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ

7.53–7.47 (m, 2H), 7.35–7.30 (m, 2H), 7.29–7.26 (m, 1H), 6.39 (d, J = 8.3 Hz, 1H), 4.49 (td, J = 9.3, 6.9 Hz, 1H), 4.43–4.36 (m, 1H), 4.26–4.19 (m, 1H), 4.15–4.09 (m, 1H), 4.00 (dd, J = 13.3, 5.1 Hz, 1H), 3.94–3.88 (m, 1H), 3.32 (td, J = 11.5, 2.3 Hz, 1H), 1.87–1.80 (m, 1H), 1.73–1.66 (m, 1H), 1.57–1.45 (m, 4H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 173.5, 135.9, 130.0, 128.5, 127.7, 79.6, 69.0, 66.1, 53.3, 47.7, 29.8, 25.9, 23.5; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 10/90, 1.0 mL/min, 275 nm), retention time: t_{major} = 17.003 min, t_{minor} = 21.647 min, ee = 96%. The NMR spectral data is consistent with reported literature values.²



(*R*)-2-Phenyl-2-((*R*)-tetrahydro-2H-pyran-2-yl)-1-(2-thioxooxazolidin-3-yl)ethan-1-one (3r')

¹H NMR (500 MHz, CDCl₃) δ 7.54–7.45 (m, 2H), 7.34–7.29 (m, 2H), 7.28–7.26 (m, 1H), 6.19 (d, J = 9.9 Hz, 1H), 4.50–4.38 (m, 2H), 4.34–4.28 (m, 1H), 4.19–4.11 (m, 1H), 4.07–4.00 (m, 1H), 3.98–3.91 (m, 1H), 3.51–3.40 (m, 1H), 1.78–1.72 (m, 1H), 1.60–1.52 (m, 1H), 1.50–1.44 (m, 1H), 1.42–1.32 (m, 1H), 1.26–1.14 (m, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 185.4, 174.2, 134.5, 129.9, 128.7, 127.9, 80.6, 68.7, 66.2, 53.8, 47.6, 29.1, 25.9, 23.3; HPLC: the ee value was determined by HPLC analysis (Chiralpak AD-H, *i*-PrOH/Hexane = 10/90, 1.0 mL/min, 274 nm), retention time: t_{minor} = 10.083 min, t_{major} = 11.173 min, ee = 95%. The NMR spectral data is consistent with reported literature values.²



(2R,3S)-3-Methoxy-2-phenyl-1-(2-thioxothiazolidin-3-yl)octan-1-one (3s)

The compounds were prepared according to general procedure using CH_2Cl_2 as solvent and purified by silica gel chromatography (CH_2Cl_2 /petroleum ether 75:25 to 100:0) affording **3s** in 27% yield (95.9 mg) and **3s'** in 27% yield (94.1 mg),

corresponding to a combined yield of 54% (190.0 mg) and a 1:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.45–7.40 (m, 2H), 7.32 (dd, J = 11.4, 4.4 Hz, 2H), 7.29–7.26 (m, 1H), 6.10 (d, J = 7.8 Hz, 1H), 4.59–4.47 (m, 2H), 3.84–3.77 (m, 1H), 3.24–3.14 (m, 2H), 3.07 (s, 3H), 1.58–1.43 (m, 3H), 1.34–1.25 (m, 5H), 0.88 (t, J = 6.9 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 201.5, 174.5, 135.8, 130.1, 128.4, 127.6, 84.0, 58.9, 56.9, 54.5, 33.2, 32.0, 28.3, 25.4, 22.7, 14.2; HPLC: the ee value was determined by HPLC analysis (Chiralpak IB-H, *i*-PrOH/Hexane = 5/95, 1.0 mL/min, 312 nm), retention time: t_{minor} = 27.060 min, t_{major} = 29.807 min, ee = 95%. The NMR spectral data is consistent with reported literature values.²



(2R,3R)-3-Methoxy-2-phenyl-1-(2-thioxothiazolidin-3-yl)octan-1-one (3s')

¹H NMR (500 MHz, CDCl₃) δ 7.45 (dt, J = 3.4, 2.0 Hz, 2H), 7.33–7.28 (m, 2H), 7.28–7.26 (m, 1H), 6.04 (d, J = 9.9 Hz, 1H), 4.66–4.58 (m, 1H), 4.48 (dt, J = 12.1, 7.9 Hz, 1H), 4.00–3.92 (m, 1H), 3.38 (s, 3H), 3.27 (dt, J = 11.0, 7.9 Hz, 1H), 3.18–3.12 (m, 1H), 1.42–1.30 (m, 2H), 1.26–1.09 (m, 6H), 0.82 (t, J = 7.2 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 201.7, 175.5, 135.5, 129.8, 128.6, 127.8, 84.5, 58.1, 56.9, 53.8, 32.1, 30.4, 28.5, 23.9, 22.7, 14.7; HPLC: the ee value was determined by HPLC analysis (Chiralpak IB-H, *i*-PrOH/Hexane = 5/95, 1.0 mL/min, 317 nm), retention time: t_{minor} = 16.240 min, t_{major} = 18.000 min, ee = 94%. The NMR spectral data is consistent with reported literature values.²



Methyl (5*R*,6*R*)-5-methoxy-7-oxo-6-phenyl-7-(2-thioxothiazolidin-3-yl) heptanoate (3t)

The compounds were prepared according to general procedure using CH2Cl2 as

solvent and purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) affording **3t** in 24% yield (90.3 mg) and **3t'** in 23% yield (88.2 mg), corresponding to a combined yield of 47% (178.5 mg, yellow oil) and a 1:1 d.r. ¹H NMR (500 MHz, CDCl₃) δ 7.45–7.40 (m, 2H), 7.34–7.30 (m, 2H), 7.30–7.27 (m, 1H), 6.12 (d, *J* = 8.0 Hz, 1H), 4.57 (dt, *J* = 12.1, 7.7 Hz, 1H), 4.48 (ddd, *J* = 12.1, 7.6, 6.9 Hz, 1H), 3.81 (td, *J* = 7.3, 3.7 Hz, 1H), 3.66 (s, 3H), 3.24 (dt, *J* = 11.3, 7.2 Hz, 1H), 3.15 (dt, *J* = 11.0, 7.7 Hz, 1H), 3.06 (s, 3H), 2.36–2.29 (m, *J* = 7.5, 2.9 Hz, 2H), 1.86–1.79 (m, 1H), 1.70–1.57 (m, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 201.6, 174.2, 174.1, 135.7, 130.0, 128.5, 127.7, 83.8, 59.0, 56.9, 54.3, 51.7, 34.0, 32.5, 28.3, 21.2; HRMS (ESI) m/z [M + H]⁺ calculated for C₁₇H₂₄NO₃S₂: 354.1192, found 354.1194; HPLC: the evalue was determined by HPLC analysis (Chiralcel IB-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 329 nm), retention time: t_{minor} = 8.780 min, t_{major} = 9.187 min, ee = 94%; [α]_D²³ = +16.0 (c = 0.20, THF).



Methyl (5*S*,6*R*)-5-methoxy-6-phenyl-6-(2-thioxothiazolidin-3-yl)hexanoate (3t') ¹H NMR (500 MHz, CDCl₃) δ 7.50–7.42 (m, 2H), 7.35–7.29 (m, *J* = 12.9, 7.6 Hz, 2H), 7.29–7.26 (m, 1H), 6.09 (d, *J* = 9.9 Hz, 1H), 4.62 (ddd, *J* = 12.1, 7.7, 6.8 Hz, 1H), 4.49 (dt, *J* = 12.1, 7.8 Hz, 1H), 3.99 (ddd, *J* = 9.7, 5.8, 3.8 Hz, 1H), 3.60 (s, 3H), 3.39 (s, 3H), 3.27 (dt, *J* = 11.0, 7.8 Hz, 1H), 3.19–3.12 (m, 1H), 2.24–2.16 (m, *J* = 11.8, 4.4 Hz, 2H), 1.70–1.57 (m, 2H), 1.48–1.41 (m, 1H), 1.18 (ddt, *J* = 14.6, 10.9, 5.4 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 201.8, 175.2, 174.0, 135.3, 129.7, 128.8, 128.0, 84.0, 58.1, 56.9, 53.6, 51.6, 34.2, 29.7, 28.5, 19.8; HRMS (ESI) m/z [M + H]⁺ calculated for C₁₇H₂₄NO₃S₂: 354.1192, found 354.1190; HPLC: the ee value was determined by HPLC analysis (Chiralcel IB-H, *i*-PrOH/Hexane = 20/80, 1.0 mL/min, 321 nm), retention time: t_{minor} = 7.767 min, t_{major} = 8.323 min, ee = 94%; $[\alpha]_D^{23} = -42.7$ (c = 0.18, THF).

Gram-scale Reaction

To a solution of **2a** (1.0 g, 4.5 mmol) in THF/CH₂Cl₂ (6.8 mL/2.3 mL) was added L5/Ni(OTf)₂ (420 mg, 0.45 mmol) at -40 °C. Then a solution of 2,4,6-collidine (1.78 mL, 13.6 mmol) and BF₃·OEt₂ (2.24 mL, 18.1 mmol) were added to the reaction mixture, and it was allowed to warm to rt in 5 min. After that, **1ab** (1.85 mL, 11.3 mmol) was added and the resulting mixture was stirred for another 2h. The solvent was removed and the residue was purified by silica gel chromatography (CH₂Cl₂/EtOAc 100:0 to 99:1) to give **3a** in 47% yield (614 mg, 96% ee) and **3a**' in 31% yield (408 mg, 94% ee), corresponding to a combined yield of 78% and a 1.5:1 d.r.

References

1.(a) Fujioka, H.; Ohnak, T.; Okitsu, T. *Heterocycles* **2007**, *72*, 529; (b) Coric, I.; Vellalath, S.; List, B. J. Am. Chem. Soc **2010**, *132*, 8536; (c) De, S. K.; Gibbs, R. A. *Tetrahedron Lett.* **2004**, *45*, 8141.

2. G. Wang, X. Xin, Z. Wang, G. Lu, Y. Ma and L. Liu, *Nature Commun.* 2019, **10**, 559.

¹H and ¹³C NMR Spectra










































7, 4743 7, 3726 7, 3726 7, 3726 7, 3726 6, 356 8, 356 8, 356 7, 36 8, 356 7, 36 8, 356 7, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8, 36 8,





























HPLC Data

 2
 12.670
 113.008
 50.29

 Total:
 224.711
 100.00

n.a.

Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		8.327	0.348	0.79	n.a.	
2		12.540	43.541	99.21	n.a.	
Total:			43.888	100.00		

Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		15.840	374.096	49.87	n.a.	
2		17.300	376.104	50.13	n.a.	

Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		11.350	128.791	49.37	n.a.	
2		15.470	132.093	50.63	n.a.	
Total:			260.884	100.00		

Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		11.373	73.103	97.44	n.a.	
2		15.463	1.917	2.56	n.a.	
Total:			75.020	100.00		

Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		9.000	198.864	49.96	n.a.	
2		11.617	199.158	50.04	n.a.	

Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		9.020	0.985	1.21	n.a.	
2		11.583	80.479	98.79	n.a.	
Total:			81.464	100.00		



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		48.877	71.460	49.30	n.a.		
2		51.437	73.500	50.70	n.a.		
Total:			144.959	100.00			



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		49.057	0.575	1.85	n.a.		
2		51.497	30.494	98.15	n.a.		
Total:			31.069	100.00			



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		20.113	145.406	49.51	n.a.		
2		22.103	148.266	50.49	n.a.		
Total:			293.672	100.00			



Integration Results								
No.	Peak Name	Retention Time	Area	Relative Area	Amount			
		min	mAU*min	%	n.a.			
1		20.097	0.923	2.62	n.a.			
2		22.007	34.274	97.38	n.a.			
Total:			35.197	100.00				



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		9.913	214.722	49.97	n.a.		
2		11.663	215.001	50.03	n.a.		
Total:			429.723	100.00			



Integration Results								
No.	Peak Name	Retention Time	Area	Relative Area	Amount			
		min	mAU*min	%	n.a.			
1		9.977	1.280	1.26	n.a.			
2		11.700	100.398	98.74	n.a.			
Total:			101.679	100.00				



	13.613	100.00
12.700	13.308	97.76
11.230	0.305	2.24
111111		70

n.a.

2

Total:





Integration Results								
No.	Peak Name	Retention Time	Area	Relative Area	Amount			
		min	mAU*min	%	n.a.			
1		8.967	0.640	1.09	n.a.			
2		11.777	58.283	98.91	n.a.			
Total:			58.924	100.00				



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		11.797	235.824	49.99	n.a.		
2		17.170	235.957	50.01	n.a.		





Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		11.743	1.744	1.65	n.a.		
2		17.243	104.158	98.35	n.a.		
Total:			105.902	100.00			



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		9.233	55.133	50.12	n.a.		
2		16.557	54.862	49.88	n.a.		
Total:			109.995	100.00			



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		9.200	0.403	1.45	n.a.		
2		16.480	27.435	98.55	n.a.		
Total:			27.838	100.00			



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		9.330	277.653	49.83	n.a.		
2		10.057	279.563	50.17	n.a.		
Total:			557.216	100.00			



Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		9.283	139.293	98.44	n.a.	
2		9.893	2.206	1.56	n.a.	
Total:			141.499	100.00		





Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		7.303	0.385	0.33	n.a.		
2		11.403	117.026	99.67	n.a.		
Total:			117.412	100.00			





Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		17.197	0.630	0.66	n.a.		
2		21.880	95.468	99.34	n.a.		
Total:			96.098	100.00			



0		•	•	•	
No.	Peak Name	Retention Time	Area	Relative Area	Amount
		min	mAU*min	%	n.a.
1		11.460	187.509	49.70	n.a.
2		17.780	189.738	50.30	n.a.
Total:			377.246	100.00	



Integration Results								
No.	Peak Name	Retention Time	Area	Relative Area	Amount			
		min	mAU*min	%	n.a.			
1		11.260	0.523	1.60	n.a.			
2		17.353	32.205	98.40	n.a.			
Total:			32.727	100.00				



0					
No.	Peak Name	Retention Time	Area	Relative Area	Amount
		min	mAU*min	%	n.a.
1		11.733	63.852	98.03	n.a.
2		14.167	1.284	1.97	n.a.
Total:			65.136	100.00	





Integration Results								
No.	Peak Name	Retention Time	Area	Relative Area	Amount			
		min	mAU*min	%	n.a.			
1		10.660	193.042	50.10	n.a.			
2		18.767	192.302	49.90	n.a.			
Total:			385.345	100.00				



integra	integration results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount			
		min	mAU*min	%	n.a.			
1		10.623	1.322	1.35	n.a.			
2		18.690	96.589	98.65	n.a.			
Total:			97.911	100.00				

















Integration Results								
No.	Peak Name	Retention Time	Area	Relative Area	Amount			
		min	mAU*min	%	n.a.			
1		17.057	2.094	4.93	n.a.			
2		21.230	40.375	95.07	n.a.			
Total:			42.469	100.00				



Total:			245.315	100.00	
2		13.367	122.631	49.99	n.a.
1		9.977	122.683	50.01	n.a.
		min	mAU*min	%	n.a.
NO.	Peak Name	Retention Time	Area	Relative Area	Amount



Integration Results								
No.	Peak Name	Retention Time	Area	Relative Area	Amount			
		min	mAU*min	%	n.a.			
1		10.003	5.147	7.31	n.a.			
2		13.390	65.233	92.69	n.a.			
Total:			70.380	100.00				



No.	Peak Name	Retention Time	Area	Relative Area	Amount
		min	mAU*min	%	n.a.
1		10.013	1.464	1.63	n.a.
2		13.200	88.322	98.37	n.a.
Total:			89.786	100.00	





Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		7.030	3.353	3.57	n.a.	
2		14.483	90.660	96.43	n.a.	
Total:			94.013	100.00		



No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		13.317	2.023	1.37	n.a.	
2		14.720	145.230	98.63	n.a.	
Total:			147.253	100.00		



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		9.770	186.055	49.85	n.a.		
2		18.283	187.141	50.15	n.a.		
Total:			373,196	100.00			



Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		9.807	102.406	98.77	n.a.	
2		18.560	1.278	1.23	n.a.	
Total:			103.684	100.00		





Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		9.287	298.565	49.99	n.a.	
2		10.383	298.704	50.01	n.a.	
Total:			597.269	100.00		



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		10.083	3.289	3.16	n.a.		
2		11.173	100.911	96.84	n.a.		
Total:			104.200	100.00			







Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		15.897	135.206	49.61	n.a.		
2		17.797	137.347	50.39	n.a.		
Total:			272.553	100.00			



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		16.240	1.267	3.24	n.a.		
2		18.000	37.878	96.76	n.a.		
Total:			39.145	100.00			





Integration Results						
No.	Peak Name	Retention Time	Area	Relative Area	Amount	
		min	mAU*min	%	n.a.	
1		7.710	9.705	49.30	n.a.	
2		8.270	9.981	50.70	n.a.	
Total:			19.686	100.00		



Integration Results							
No.	Peak Name	Retention Time	Area	Relative Area	Amount		
		min	mAU*min	%	n.a.		
1		7.767	0.264	3.19	n.a.		
2		8.323	8.010	96.81	n.a.		
Total:			8.274	100.00			